New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Sanofi

SNY

Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.

Revenue
+13.9%
EPS
+8.21%
Free cash flow
+99.6%
Total debt
−11.2%

Quarter to September 2026, against a year earlier

46.59 0.53 +1.15%
Market cap
$111.3B
P/E
22.8×
Fwd P/E FY26e
—
Dividend yield
5.25%
F-score
7/9
ROIC
7.05%
Net debt / EBITDA
0.8×
Payout ratio
1.2×

Ratios over time FY16 to FY25

Returns on capital

ROIC was 6.57% in FY25, against a low of 4.30% in FY18.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE8.1%14.7%7.5%4.6%20.3%9.6%11.0%7.3%7.3%10.7%
ROIC6.5%6.2%4.3%5.5%12.5%6.6%7.8%6.8%5.5%6.6%

Debt

Net debt is 0.76× a year’s EBITDA. Debt is 0.26× equity, against 0.42× in FY19.

Debt / equityNet debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Debt / equity0.3×0.3×0.4×0.4×0.4×0.3×0.3×0.2×0.2×0.3×
Net debt / EBITDA0.8×0.5×1.9×1.1×0.5×0.9×0.5×0.6×0.8×0.8×

Cash cycle, in days

Customers pay in 69 days, inventory is held 286 days and suppliers are paid in 206. Cash is tied up for 149 days between paying for goods and being paid.

Cash cycleDays to pay suppliersDays to be paid
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Cash cycle165141152159165152128129121149
Days to pay suppliers147146161162159184182188209206
Days to be paid77737477737671696969

Per share, from FY16

Since FY16, per share: free cash flow has grown 4.27% a year; revenue has grown 4.22% a year; book value has grown 3.30% a year.

Free cash flowRevenueBook value
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Free cash flow1.0×1.0×1.1×1.2×1.1×1.7×1.6×1.4×1.2×1.5×
Revenue1.0×1.1×1.1×1.1×1.1×1.2×1.3×1.3×1.3×1.5×
Book value1.0×1.1×1.1×1.1×1.2×1.3×1.3×1.3×1.4×1.3×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
13.46 20.08 21.19 13.80 6.59 3.74 12.95 12.01 24.17 20.11
Piotroski F-Score
7 7 5 8 7 5 5 5 7 8
P/S ratio
2.24 2.52 2.49 2.57 1.87 1.91 2.04 2.06 2.66 2.75
Altman Z-Score
2.50 2.58 2.73 2.79 2.62 2.87 2.51 2.25 2.87 2.52
P/FCF ratio
6.36 5.88 4.84 4.76 6.77 8.02 7.33 5.77 6.34 7.58
Altman Z″-Score (non-manufacturers)
3.68 4.21 4.05 4.31 4.09 4.67 3.52 3.44 4.45 3.90
Beneish M-Score
(2.63) (2.66) (2.63) (2.59) (2.48) (2.24) (2.70) (2.52) (2.63) (2.66)
P/Operating CF
9.73 12.28 11.27 11.06 19.23 28.27 24.50 25.08 13.06 12.17
P/B ratio
1.46 1.43 1.56 1.55 1.62 1.58 1.90 1.61 1.65 1.65
EV/Sales
2.47 2.71 2.66 2.70 2.08 2.10 2.33 2.44 2.81 2.99
EV/EBITDA
13.29 15.81 13.91 12.06 6.98 7.42 7.43 11.37 16.25 15.11
EV/FCF
7.02 6.33 5.16 5.01 7.52 8.80 8.39 6.84 6.69 8.24
Current Ratio
1.09 1.46 1.27 1.42 1.44 1.75 1.40 1.41 1.70 1.62
Net Debt/EBITDA
0.76 0.77 0.56 0.46 0.87 0.48 1.09 1.85 0.53 0.82
Debt/Equity
0.26 0.21 0.22 0.25 0.29 0.36 0.42 0.42 0.27 0.32
ROE
10.69% 7.31% 7.32% 10.97% 9.57% 20.34% 4.62% 7.50% 14.70% 8.11%
ROA
6.16% 4.29% 4.32% 6.40% 5.39% 10.94% 2.44% 4.16% 8.34% 4.54%
ROIC
6.57% 5.49% 6.75% 7.81% 6.56% 12.50% 5.46% 4.30% 6.15% 6.49%
Return on Tangible Assets
61.72% 23.64% 32.46% 42.00% 32.25% 51.70% 15.63% 25.55% 41.19% 23.23%
Average Days of Receivables
68.81 69.24 69.35 70.75 76.21 73.17 76.98 74.27 72.75 76.88
Earnings Yield
7.43% 4.98% 4.72% 7.24% 15.19% 26.70% 7.72% 8.33% 4.14% 4.97%
Free Cash Flow Yield
15.73% 17.01% 20.68% 21.03% 14.78% 12.47% 13.64% 17.34% 15.77% 13.20%
Free Cash Flow per Share
3.74 3.18 3.57 4.13 4.34 2.85 3.20 2.71 2.68 2.56
Book value per Share
33.24 33.66 32.15 31.62 32.60 28.77 26.48 27.95 26.20 24.82
Free Cash Flow
9,117.95 7,950.19 8,927.89 10,338.97 10,880.97 7,142.80 8,010.24 6,770.67 6,734.33 6,599.76
EV/EBIT
13.29 15.81 13.91 12.06 12.32 14.49 21.18 19.01 16.25 15.11
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 5, 2026